Cingulate Inc.CING

Cingulate Inc. (CING) is a biopharmaceutical company focused on developing treatments for ADHD and anxiety disorders using its proprietary Precision Timed Release™ (PTR™) technology. The company’s latest press release highlights its dexmethylphenidate HCl product, a once-daily, multi-core tablet designed to provide precise and sustained drug delivery. This innovative approach aims to improve patient compliance and therapeutic outcomes, positioning Cingulate as a potential leader in the ADHD treatment market.

Despite its promising technology, Cingulate’s financial performance paints a starkly different picture. The company reported a net income (loss) attributable to parent of $-9.3 million for the period ending 2026-03-31, with operating income (loss) of $-7.9 million. Cash and cash equivalents stood at $25.9 million, down from previous periods, highlighting the company’s ongoing cash burn. Research and development expenses totaled $2.2 million, reflecting the significant investment required to advance its drug pipeline.

The company’s financial health is further scrutinized by its balance sheet. Total assets were reported at $30.9 million, with liabilities of $12.0 million and stockholders’ equity of $18.9 million. The weighted average number of shares outstanding, diluted, was 9.8 million, indicating potential dilution concerns for existing shareholders. Earnings per share, diluted, were $-0.95, underscoring the company’s struggle to achieve profitability.

Cingulate’s market performance and financial metrics suggest a high-risk, high-reward profile. The company’s innovative PTR technology and potential market-leading products are offset by significant cash burn and financial losses. The source directs readers to carefully consider the company’s ability to secure additional funding, achieve regulatory approvals, and ultimately generate revenue from its drug pipeline.